Comparative Pharmacology
Head-to-head clinical analysis: LIORESAL versus PARSIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIORESAL versus PARSIDOL.
LIORESAL vs PARSIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.
Parsidol (ethopropazine) is a phenothiazine derivative that acts as an anticholinergic agent. It inhibits the action of acetylcholine at muscarinic receptors, thereby reducing cholinergic activity in the basal ganglia and restoring the balance between dopaminergic and cholinergic neurotransmission. It also has some dopamine reuptake inhibition and antihistaminic properties.
Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.
Oral: 2.5-5 mg twice daily, gradually increased to 5-10 mg three times daily; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2.5-4 hours. Clinically, accumulation occurs in renal impairment, requiring dose adjustment.
Terminal elimination half-life: 12-24 hours (prolonged in elderly and renal impairment, requiring dose adjustment).
Renal: approximately 70-80% of the dose as unchanged drug and metabolites (primarily glucuronide conjugate); minor biliary/fecal elimination (<5%).
Renal: 60-70% as unchanged drug; biliary/fecal: 15-20% as metabolites; minor respiratory elimination.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant